Novartis is gearing up to auction its U.S. generic pill business, a unit that has struggled amid fierce competition, a move pointing to the idea that biosimilars will be the end of ‘big pharma’.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Roche has announced that it intends to purchase the rest of the U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.
Biological drugs are complex molecules made in living cells, and they have changed medicine in the past two decades, offering rich choices for companies making almost identical copies as patents expire.
The Food and Drug Administration (FDA) has been busy this week. Their most recent approval is for Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.
Britain’s Oxford BioMedica has a lot to be happy about right now, since its win in a second $100 million contract to supply gene therapy material from Bioverativ.
With Brexit discussions still ongoing, GlaxoSmithKline’s chief executive, Emma Walmsley is taking no chances as she urges the government to sign a two-year transition deal by April to ensure the industry can cope.
Gilead Sciences has moved closer to capturing more of the multibillion-dollar HIV drug market, with its recent drug approval from the U.S. Food and Drug Administration.
Pfizer has announced a two-year collaboration with DL Medicine, intended to produce new chemical entities against preselected targets from multiple therapeutic areas.
European drugmaker and the world’s biggest insulin maker, Novo Nordisk, wants to prove it can transform the diabetes market with a pill.